Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Am J Prev Med. 2023 Jan 13;64(6):893–897. doi: 10.1016/j.amepre.2022.12.010

Table 1:

Baseline demographics

Variables Control Intervention
N 20 20
Age, years 12.5 (2.6) 12.5 (2.9)
 8 – 12 10 (50%) 10 (50%)
 13 – 17 10 (50%) 10 (50%)
Sex, female 10 (50%) 10 (50%)
Race
 Black 9 (45%) 6 (30%)
 White 8 (40%) 10 (50%)
 More than 1 3 (15%) 4 (20%)
Asthma severitya
 Mild 4 (20%) 5 (25%)
 Moderate/Severe 16 (80%) 15 (75%)
Health insurance, Medicaid 10 (50%) 11 (55%)
Current second-hand tobacco smoke exposure, yes 7 (35%) 4 (20%)
Body mass index, z score 1.51 (1.35) 1.03 (1.22)
Forced expiratory volume in 1 second (FEV1), percent predictedb 102.2 (14.1) 97.3 (16.7)
FEV1/Forced vital capacity, percent predictedb 94.6 (7.0) 88.0 (9.0)
Severe asthma exacerbation in last 12 monthsc, yes 11 (55%) 13 (65%)
Asthma Control Test (n=13 per group) 20.9 (4.6) 21.2 (3.0)
Childhood Asthma Control Test (n=7 per group) 22.6 (1.3) 20.7 (8.3)
Pediatric Asthma Quality of Life Questionnaire 5.96 (1.02) 6.11 (0.84)
Checked Air Quality Index (AQI) prior to outdoor activity, yes 2 (10%) 2 (10%)
Reported any change in outdoor activity in response to AQI, yes 5 (25%) 3 (15%)
Moderate or vigorous outdoor physical activity in typical week, yes 14 (70%) 18 (90%)

Notes: Results displayed as N (%) or mean (SD).

a

Severity was determined by therapy as per asthma action plan: step 2- mild, step 3 & 4- moderate, step 5 & 6- severe. Children receiving a biologic immunomodulator but no oral corticosteroids were categorized as step 5.

b

Spirometry percent predicted based on GLI2012 prediction equations.

c

Asthma exacerbation history obtained via parental-report, severe asthma exacerbation defined as reporting systemic steroids or an emergency department/urgent care visit or hospitalization for asthma.